Histone Deacetylase Inhibitors in Cancer Therapy

(E-pub Ahead of Print)

Author(s): Yijie Sun, Fanghui Lu *, Yanyi Sun , Saichao Yue, Yaohe Wang .

Journal Name: Current Topics in Medicinal Chemistry


Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments have been discorvered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistical effects in combinational treatment.

Keywords: Histone Deacetylase, Inhibitors, Epigenetics, Cancer treatment

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1568026619666181210152115
Price: $95